Search details
1.
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Breast Cancer Res Treat
; 204(2): 237-248, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38112922
2.
Risk of Lymphedema Following Contemporary Treatment for Breast Cancer: An Analysis of 7617 Consecutive Patients From a Multidisciplinary Perspective.
Ann Surg
; 274(1): 170-178, 2021 07 01.
Article
in English
| MEDLINE | ID: mdl-31348041
3.
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
Oncologist
; 26(1): e53-e65, 2021 01.
Article
in English
| MEDLINE | ID: mdl-32955138
4.
Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations.
Invest New Drugs
; 39(5): 1366-1374, 2021 10.
Article
in English
| MEDLINE | ID: mdl-33723724
5.
A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy.
Invest New Drugs
; 38(3): 866-873, 2020 06.
Article
in English
| MEDLINE | ID: mdl-31728715
6.
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial.
Int J Cancer
; 143(12): 3240-3247, 2018 12 15.
Article
in English
| MEDLINE | ID: mdl-29978467
7.
8.
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
Oncologist
; 26(3): e522, 2021 Mar.
Article
in English
| MEDLINE | ID: mdl-33660385
9.
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
Lancet Oncol
; 16(16): 1700-10, 2015 Dec.
Article
in English
| MEDLINE | ID: mdl-26596672
10.
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02).
Breast Cancer Res Treat
; 152(1): 77-85, 2015 Jul.
Article
in English
| MEDLINE | ID: mdl-26033708
11.
Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
Cancer
; 120(5): 642-51, 2014 Mar 01.
Article
in English
| MEDLINE | ID: mdl-24222194
12.
Detection of circulating tumor cells in patients with breast cancer using the quantitative RT-PCR assay for monitoring of therapy efficacy.
Exp Mol Pathol
; 97(3): 445-52, 2014 Dec.
Article
in English
| MEDLINE | ID: mdl-25217799
13.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
Lancet
; 379(9816): 633-40, 2012 Feb 18.
Article
in English
| MEDLINE | ID: mdl-22257673
14.
Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors.
Support Care Cancer
; 21(6): 1751-9, 2013 Jun.
Article
in English
| MEDLINE | ID: mdl-23338230
15.
Machine Learning Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy for ER+HER2- Breast Cancer: Integrating Tumoral and Peritumoral MRI Radiomic Features.
Diagnostics (Basel)
; 13(19)2023 Sep 23.
Article
in English
| MEDLINE | ID: mdl-37835774
16.
Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea.
Palliat Med Rep
; 4(1): 9-16, 2023.
Article
in English
| MEDLINE | ID: mdl-36743339
17.
Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNA.
Nat Commun
; 14(1): 2017, 2023 04 10.
Article
in English
| MEDLINE | ID: mdl-37037826
18.
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial.
JAMA Oncol
; 8(9): 1271-1277, 2022 09 01.
Article
in English
| MEDLINE | ID: mdl-35797012
19.
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
J Clin Oncol
; 40(28): 3246-3256, 2022 10 01.
Article
in English
| MEDLINE | ID: mdl-35584336
20.
Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer.
Pharmaceuticals (Basel)
; 14(10)2021 Sep 30.
Article
in English
| MEDLINE | ID: mdl-34681231